Medtronic Receives Approval for U.S. Labeling of the Intelli

Medtronic Receives Approval for U.S. Labeling of the Intellis Platform Showing Superior Back Pain Relief When Using DTM Spinal Cord Stimulation
Medtronic plc the global leader in medical technology, today announced the U.S. Food and Drug Administration has approved revised commercial labeling for the Intellis™ Platform with Differential Target Multiplexed programming for the treatment of chronic, intractable back and leg pain. The new labeling will include study outcomes from a multicenter randomized control trial reflecting superior back pain relief with …
Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) has approved revised commercial labeling for the Intellis™ Platform with Differential Target Multiplexed (DTM™) programming for the treatment of chronic, intractable back and leg pain. The new labeling will include study outcomes from a multicenter randomized control trial reflecting superior back pain relief with DTM SCS when compared to conventional SCS.

Related Keywords

Nevada , United States , Ireland , Dublin , Medtronic Intellis , Ryan Weispfenning , Las Vegas , Jeff Trauring , Exchange Commission , American Neuromodulation Society , Drug Administration , Medtronic , Differential Target Multiplexed , Visual Analog Scale , Charlie Covert , Pain Therapies , Neuroscience Portfolio , Controlled Clinical Trial , Treating Intractable Chronic Low Back Pain , North American Neuromodulation Society , Long Term Follow Up , நெவாடா , ஒன்றுபட்டது மாநிலங்களில் , ஐயர்ல்யாஂட் , டப்ளின் , லாஸ் வேகாஸ் , ஜெஃப் இழுவை , பரிமாற்றம் தரகு , மெதிடிறோனிக் , காட்சி அனலாக் அளவு , சார்லி இரகசிய , வலி சிகிச்சைகள் , நரம்பியல் போர்ட்‌ஃபோலீயோ , கட்டுப்படுத்தப்படுகிறது மருத்துவ சோதனை , நீண்டது கால பின்தொடரவும் மேலே ,